Home         Forums  

Go Back   Marrowforums > Treatments > Drugs and Drug Treatments
Register FAQ Search Today's Posts Mark Forums Read

Drugs and Drug Treatments ATG, Cyclosporine, Revlimid, Vidaza, Dacogen, ...

Reply
 
Thread Tools Search this Thread
  #1  
Old Fri Aug 1, 2008, 02:51 PM
Birgitta-A Birgitta-A is offline
Member
 
Join Date: Oct 2007
Location: Stockholm, Sweden
Posts: 1,918
Exclamation Revlimid not approved for MDS in EU due to risk for AML

Hi all,
Revlimid has not been approved for MDS in Europe due to risk for AML transformation. Look at the last of the 51 pages.
http://www.emea.europa.eu/humandocs/...688-WAR-en.pdf
Kind regards
Birgitta-A
Reply With Quote
  #2  
Old Sat Aug 2, 2008, 10:06 PM
Ruth Cuadra Ruth Cuadra is offline
Administrator
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 612
Just to be clear, the European study did not implicate Revlimid in causing MDS to transform to AML. There were problems with the study design that did not produce enough comparative data to show sufficient benefit from lenalidomide to warrant the risks. Here is the key passage from the study's conclusions:
Therefore, the data provided were insufficient to demonstrate a favourable benefit/risk balance of lenalidomide in the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a 5q deletion with or without additional cytogenetic abnormalities, or an isolated deletion 5q cytogenetic abnormality...
Regards,
Ruth
__________________
Diagnosed AA 10/96, MDS/RA 6/98, MUD/BMT 10/6/98
Reply With Quote
  #3  
Old Wed Aug 20, 2008, 01:16 AM
Neil Cuadra Neil Cuadra is offline
Owner
 
Join Date: Jul 2006
Location: Los Angeles, California
Posts: 2,504
There is a very readable question-and-answer document from the European Medicines Agency (EMEA):
Questions and Answers on Recommendation for the Refusal of the Marketing Authorisation for Lenalidomide Celgene Europe (PDF, 36K)

Note: If the page displays "garbage", reload the page for the correct display.
As it explains:
The CHMP had concerns over the way the main study was carried out, which meant that the safety of Lenalidomide Celgene Europe was difficult to assess. In particular, because the study did not compare the medicine to any other treatment, it was difficult to determine if treatment with Lenalidomide Celgene Europe increased the risk of progression to acute myeloid leukaemia.
It also explains that patients in trials and those who petition for "compassionate use" may still have access to the drug:
The company informed the CHMP that it will continue to make lenalidomide available for patients included in clinical trials or compassionate use programmes. If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump

Similar Threads
Thread Thread Starter Forum Replies Last Post
Revlimid and High Risk MDS RAEB 2 - 18% Blasts Peachy MDS 21 Tue Mar 17, 2015 02:42 PM
The lower risk MDS patient at risk of rapid progression akita MDS 0 Mon Dec 27, 2010 04:28 AM
Revlimid and low risk/high risk MDS Birgitta-A Drugs and Drug Treatments 2 Mon May 4, 2009 12:21 PM


All times are GMT -4. The time now is 06:02 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright 2006-2020 Marrowforums.org